- Global Pharma News & Resources

Dilated Cardiomyopathy Market Industry 2019 Global Analysis, Size, Trends, Share, Growth, Competitive Landscape, Key Players, Regional And Industry Forecast To 2026

Global Dilated cardiomyopathy (DCM) is a condition, in which the heart’s ability to pump blood is decreased due to enlarging of heart’s main pumping chamber. This can affect the functioning of other organs such as lungs, liver, and kidney. In this disease, the heart muscles begin to dilate (stretch), which results in thinning and elongation of the chamber. In fact, it further spreads to the right ventricle and atria’s. Due to this, normal contraction of heart muscles hinders and so does the normal pumping of blood. Furthermore, heart becomes weak, which can ultimately leads to heart failure.

Get Sample PDF Brochure with Impact of COVID19:

The symptoms such as fatigue, edema in ankles, legs, feet, veins in the neck and abdomen are quite common in this case. There are various reasons for dilated cardiomyopathy are uncontrolled blood pressure, viral infection, excessive amount of alcohol, and problem with heart valve. Although there is no proper drug to control DCM, doctors prescribe congestive heart failure drugs for its treatment. DCM is majorly found in people of age group 20-60 years old and very seldom in children. It is primarily diagnosed with electrocardiogram, X-ray, and MRI. Implantable devices such as ‘Implantable Cardioverter Defibrillator (ICD) and pacemaker are implanted in the high risk patients, in order to maintain the proper rhythmic functioning of the heart so as to avoid risk of cardiac arrest. According to British Heart Foundation, in 2015, there were around 25,000 implants of pacemaker implanted every year in the U.K.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Dilated cardiomyopathy market taxonomy:

By Drugs

  • Blood thinning medications
  • Beta Blockers
  • Cardiac glycosides
  • Angiotensin-Converting Enzyme (ACE) inhibitors
  • Angiotensin II receptor blockers

By Device

  • Implantable Devices
  • Cardioverter-Defibrillators
  • Heart Pumps

By Distribution

  • Retails Pharmacies
  • Mail order Pharmacies
  • Online pharmacies
  • Hospital Pharmacies

By Geography

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East
  • Africa

Rise in congestive heart failure to drive growth of the global dilated cardiomyopathy market

Growing prevalence of congestive heart failure cases, which leads to the increase in dilated cardiomyopathy cases is expected to drive the market growth. According to American Heart Association, in 2016, there were around 5.7 million adults in the U.S. who suffered from heart failure. However, there is no drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of dilated cardiomyopathy. Moreover, key companies in the market are investing in research and development of new drugs such as ARRY-797 and Ixmyelocel-T, which is expected to support the growth of dilated cardiomyopathy market.

To understand Research Methodology, please click

Market Restraints

However, increased use of defibrillators, pacemaker, and lack of proper drugs is expected to restrain growth of the global dilated cardiomyopathy market

Developed regions are major growth engine of the global dilated cardiomyopathy market

Global dilated cardiomyopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Among regions, North America holds the significant share in the global dilated cardiomyopathy market, owing to increase in congestive heart failure cases in the region. Furthermore, Europe accounts for the second largest in the market. According to, European Heart Network 2017 report, there are around 3.9 million deaths caused by cardiovascular disease in Europe and over 1.8 million deaths in the Europe Union. Furthermore, Asia Pacific is the third largest market and expected to grow at a higher rate due to increased awareness of cardiovascular disease and demand of generic drugs is expected to support the growth of the market

Key players of global dilated cardiomyopathy market

There are various players in the global dilated cardiomyopathy market present across the globe, which contributes to the DCM market. Some key players are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Array BioPharma, AstraZeneca, GlaxoSmithKline Plc., and Sanofi.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 03-Mar-2021